carbapenems has been researched along with celastrol in 1 studies
| Studies (carbapenems) | Trials (carbapenems) | Recent Studies (post-2010) (carbapenems) | Studies (celastrol) | Trials (celastrol) | Recent Studies (post-2010) (celastrol) |
|---|---|---|---|---|---|
| 7,355 | 147 | 5,277 | 885 | 1 | 741 |
| Protein | Taxonomy | carbapenems (IC50) | celastrol (IC50) |
|---|---|---|---|
| Telomerase reverse transcriptase | Homo sapiens (human) | 0.78 | |
| Ubiquitin carboxyl-terminal hydrolase 2 | Homo sapiens (human) | 6.8 | |
| Ubiquitin carboxyl-terminal hydrolase isozyme L1 | Homo sapiens (human) | 6.8 | |
| Indoleamine 2,3-dioxygenase 1 | Homo sapiens (human) | 8.41 | |
| Ubiquitin carboxyl-terminal hydrolase isozyme L3 | Homo sapiens (human) | 6.8 | |
| Tyrosine-protein phosphatase non-receptor type 1 | Homo sapiens (human) | 3.45 | |
| Tyrosine-protein phosphatase non-receptor type 6 | Homo sapiens (human) | 3.1 | |
| Tyrosine-protein phosphatase non-receptor type 11 | Homo sapiens (human) | 3.5667 | |
| Hypoxia-inducible factor 1-alpha | Homo sapiens (human) | 0.25 | |
| Regulator of G-protein signaling 17 | Homo sapiens (human) | 6.1795 | |
| Ubiquitin carboxyl-terminal hydrolase 15 | Homo sapiens (human) | 6.8 | |
| Ubiquitin carboxyl-terminal hydrolase isozyme L5 | Homo sapiens (human) | 6.8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdel-Halim, MS; Askoura, M; El-Ganiny, AM; Mansour, B; Yahya, G | 1 |
1 other study(ies) available for carbapenems and celastrol
| Article | Year |
|---|---|
In vitro activity of celastrol in combination with thymol against carbapenem-resistant Klebsiella pneumoniae isolates.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Humans; Klebsiella Infections; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Molecular Docking Simulation; Thymol | 2022 |